{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:28:32Z","timestamp":1793978912936,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20525"],"award-info":[{"award-number":["U23A20525"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404408"],"award-info":[{"award-number":["82404408"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119297","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:54:25Z","timestamp":1788364465000},"page":"119297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design and optimization of 5-hydroxy-4H-benzo[1,4]oxazin-3-one-derived \u03b22-adrenoceptor agonists with potent anti-asthmatic activity"],"prefix":"10.1016","volume":"319","author":[{"given":"Lanyan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxing","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9073-4806","authenticated-orcid":false,"given":"Maosheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119297_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-020-00785-1","article-title":"Asthma epidemiology and risk factors","volume":"42","author":"Stern","year":"2020","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.ejmech.2026.119297_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00440-2022","article-title":"Planetary respiratory health for asthma, rhinoconjunctivitis and eczema","volume":"60","author":"Soriano","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2026.119297_bib3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejmech.2026.119297_bib4","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","article-title":"Asthma","volume":"401","author":"Porsbjerg","year":"2023","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejmech.2026.119297_bib5","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jaci.2024.01.024","article-title":"Update on asthma biology","volume":"153","author":"Georas","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2026.119297_bib6","doi-asserted-by":"crossref","first-page":"ITC49","DOI":"10.7326\/AITC201910010","article-title":"Asthma","volume":"171","author":"King-Biggs","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejmech.2026.119297_bib7","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.2018.3808","article-title":"Medications for asthma","volume":"319","author":"Sobieraj","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2026.119297_bib8","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.jaip.2022.03.027","article-title":"Long-term use of short-acting beta(2)-Agonists in patients with adult-onset asthma","volume":"10","author":"Vahatalo","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.ejmech.2026.119297_bib9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1183\/09031936.93.04020218","article-title":"Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma","volume":"4","author":"Lofdahl","year":"1991","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2026.119297_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1378\/chest.118.2.303","article-title":"Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma","volume":"118","author":"ZuWallack","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2026.119297_bib11","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jaad.2017.11.056","article-title":"Phosphodiesterase 4 inhibitors","volume":"78","author":"Zebda","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejmech.2026.119297_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12016-020-08776-8","article-title":"The current state of biologic therapies for treatment of refractory asthma","volume":"59","author":"Mavissakalian","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.ejmech.2026.119297_bib13","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0140-6736(95)91775-6","article-title":"Salbutamol in the treatment of asthma","volume":"346","author":"Perrin-Fayolle","year":"1995","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejmech.2026.119297_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214207","article-title":"Salbutamol in the management of asthma: a review","volume":"23","author":"Marques","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119297_bib15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00003495-199754020-00011","article-title":"Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma","volume":"54","author":"Adkins","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119297_bib16","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41589-018-0145-x","article-title":"Structural insights into binding specificity, efficacy and bias of a beta(2)AR partial agonist","volume":"14","author":"Masureel","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119297_bib17","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1016\/j.bmcl.2009.10.013","article-title":"Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as beta2-adrenoceptor agonists","volume":"19","author":"Hoenke","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119297_bib18","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.bmcl.2009.12.087","article-title":"Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy","volume":"20","author":"Bouyssou","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119297_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1183\/09031936.93.02040325","article-title":"Formoterol, a new long-acting bronchodilator for inhalation","volume":"2","author":"Arvidsson","year":"1989","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2026.119297_bib20","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/02770903.2020.1761382","article-title":"Identifying the drivers of patients' reliance on short-acting beta2-agonists in asthma","volume":"58","author":"Blakeston","year":"2021","journal-title":"J. Asthma"},{"key":"10.1016\/j.ejmech.2026.119297_bib21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/00002512-200825050-00005","article-title":"Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing","volume":"25","author":"Gupta","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejmech.2026.119297_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14093153","article-title":"Biologic therapies for severe asthma: current insights and future directions","volume":"14","author":"Faria","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2026.119297_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/resp.12957","article-title":"Severe asthma: current management, targeted therapies and future directions-A roundtable report","volume":"22","author":"McDonald","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.ejmech.2026.119297_bib24","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1021\/acs.jmedchem.3c02074","article-title":"Discovery and identification of novel 5-Hydroxy-4H-benzo[1,4]oxazin-3-one derivatives as potent beta(2)-Adrenoceptor agonists through structure-based design, synthesis, and biological evaluation","volume":"67","author":"Xing","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119297_bib25","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1038\/s41467-023-37808-y","article-title":"Constrained catecholamines gain beta(2)AR selectivity through allosteric effects on pocket dynamics","volume":"14","author":"Xu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119297_bib26","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature23652","article-title":"Mechanism of intracellular allosteric beta(2)AR antagonist revealed by X-ray crystal structure","volume":"548","author":"Liu","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119297_bib28","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1111\/j.1476-5381.2011.01639.x","article-title":"Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting beta2-adrenoceptor agonists","volume":"165","author":"Sykes","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119297_bib29","first-page":"1","article-title":"Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists","volume":"174","author":"Linden","year":"1996","journal-title":"Lung"},{"key":"10.1016\/j.ejmech.2026.119297_bib30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1055\/s-2002-20059","article-title":"Mechanisms of relaxant action of 3-O-methylquercetin in isolated Guinea pig trachea","volume":"68","author":"Ko","year":"2002","journal-title":"Planta Med."},{"key":"10.1016\/j.ejmech.2026.119297_bib31","first-page":"1538","article-title":"Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease","volume":"15","author":"Wang","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejmech.2026.119297_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1149203","article-title":"T-helper cells and their cytokines in pathogenesis and treatment of asthma","volume":"14","author":"Ji","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119297_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41421-020-0176-9","article-title":"Single-particle cryo-EM structural studies of the beta(2)AR-Gs complex bound with a full agonist formoterol","volume":"6","author":"Zhang","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.ejmech.2026.119297_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.molcel.2020.08.001","article-title":"Structural basis of the activation of heterotrimeric Gs-Protein by isoproterenol-bound \u03b21-Adrenergic receptor","volume":"80","author":"Su","year":"2020","journal-title":"Mol. Cells"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:06:44Z","timestamp":1793977604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":33,"alternative-id":["S0223523426007427"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119297","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and optimization of 5-hydroxy-4H-benzo[1,4]oxazin-3-one-derived \u03b22-adrenoceptor agonists with potent anti-asthmatic activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119297","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119297"}}